In contrast, the prognosis for BRCA1/BRCA2 mutation carriers with ER-negative tumors, even with early BC onset, is comparable with ER-positive, older BC non-carriers, who are generally considered lower-risk patients. The gene discussed is BRCA2; the disease is breast cancer.